COSMO Pharmaceuticals N.V. (COPN) AI Stock Analysis

• Market Cap: CHF1.95B
• Dividend Yield: 1.82%
• Average Volume (3M): 19.52K
• Price to Earnings (P/E): 35.6
• Beta (1Y): 0.91
• Revenue Growth: -3.44%
• EPS Growth: -21.64%
• Country: CH
• Employees: 321
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): -0.12
• Shares Outstanding: 17,543,522
• 10 Day Avg. Volume: 18,700
• 30 Day Avg. Volume: 19,520
• PEG Ratio: >-0.01
• Price to Book (P/B): 2.22
• Price to Sales (P/S): 4.15
• P/FCF Ratio: 7.07
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: CHF130.00
• Price Target Upside: 12.26% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 69 Neutral
• Price Target: CHF127.00 ▲(9.67% Upside)

COSMO Pharmaceuticals N.V. demonstrates strong financial performance with significant revenue and profit growth, supported by a robust balance sheet and excellent cash flow generation. However, the technical analysis indicates overbought conditions, and the valuation suggests the stock may be overvalued. These factors combined result in a moderate overall stock score.

Positive Factors

Balance Sheet Strength

Extremely low leverage and a high equity ratio provide durable financial flexibility to fund R&D, commercial scale-up, or M&A without heavy borrowing. Strong ROE indicates efficient capital use, reducing refinancing risk and supporting long-term strategic optionality across business cycles.

Cash Generation

A very large improvement in free cash flow and FCF/net income ratios above 1.0 show the business can convert profits into cash sustainably. This strengthens self-funding capacity for pipeline investment, commercial expansion and reduces dependency on external capital over the medium term.

High Profitability

Very high gross and net margins suggest durable product economics likely driven by proprietary formulations and efficient manufacturing. Combined with strong recent revenue expansion, margins support sustained cash generation and reinvestment capacity, enhancing long-term competitive positioning.

Negative Factors

Earnings Growth Weakness

Negative EPS growth is a structural warning sign that underlying earnings power has weakened recently. Persistent EPS declines can constrain reinvestment, limit dividend or buyback optionality, and indicate profitability volatility that could undermine long-term investor confidence if not reversed.

Revenue Volatility / Data Inconsistency

Conflicting growth metrics point to volatile or lumpy revenue recognition and potential inconsistency in top-line drivers. For a small, product-focused pharma, such volatility can impede forecasting, strain working capital planning, and make long-term revenue predictability and investment planning harder.

Dependence on Licensing & Partnerships

Heavy reliance on licensing, milestone payments and partner execution makes revenue lumpy and dependent on third-party commercialization capabilities. Partner delays or contract risks can materially affect cash flows and growth visibility, increasing structural execution risk over time.

COSMO Pharmaceuticals N.V. Business Overview & Revenue Model

Company Description

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

How the Company Makes Money

COSMO Pharmaceuticals generates revenue primarily through the sale of its proprietary pharmaceutical products and licensing agreements. The company earns money by commercializing its drugs, which are often sold directly to healthcare providers or through partnerships with larger pharmaceutical companies. Key revenue streams include royalties from licensing agreements, product sales, and potentially milestone payments from collaborative partnerships. Additionally, COSMO has established strategic alliances with other pharmaceutical firms to co-develop and market its products, which further enhances its revenue potential. The company's focus on niche markets in gastrointestinal therapies also allows it to capture specialized segments of the healthcare market.

COSMO Pharmaceuticals N.V. Financial Statement Overview

Summary

COSMO Pharmaceuticals N.V. has shown remarkable financial improvements with strong revenue and profit growth. The company maintains a robust balance sheet with minimal debt, high equity, and strong cash flow generation. This financial strength positions the company well for future growth and investment opportunities.

Income Statement

The company demonstrated a significant improvement in financial performance. Gross profit margin improved to 92.56%, and net profit margin rose to 49.94% from negative figures in prior years. Revenue grew by 187.52% from 2023 to 2024, indicating strong operational execution. However, the EBIT and EBITDA margins show a positive trend, reflecting good cost management with EBIT margin at 55.80% and EBITDA margin at 62.11%.

Balance Sheet

The debt-to-equity ratio is low at 0.004, indicating very minimal leverage, which provides financial stability. Return on equity is strong at 26.74%, demonstrating efficient use of equity. The equity ratio is robust at 77.04%, suggesting a strong financial foundation. Overall, the balance sheet reflects a stable financial position with low risk.

Cash Flow

The company's cash flow from operations improved significantly, with a free cash flow growth rate of 755.99% from 2023 to 2024, indicating excellent cash generation capabilities. The operating cash flow to net income ratio is 1.22, and the free cash flow to net income ratio is 1.18, both suggesting strong cash flow in relation to earnings.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	182.27M	266.79M	92.78M	102.09M	65.07M	60.95M
Gross Profit	159.99M	246.92M	53.44M	83.33M	49.93M	50.51M
EBITDA	76.31M	165.71M	19.70M	46.74M	17.81M	7.84M
Net Income	55.24M	133.24M	-4.93M	17.23M	21.67M	-7.90M
Balance Sheet
Total Assets	610.33M	646.77M	553.98M	759.59M	805.56M	596.16M
Cash, Cash Equivalents and Short-Term Investments	126.63M	142.96M	50.27M	240.95M	222.21M	212.85M
Total Debt	2.70M	2.20M	1.84M	173.60M	169.92M	168.14M
Total Liabilities	143.35M	141.68M	124.94M	295.80M	292.88M	196.04M
Stockholders Equity	460.24M	498.33M	422.16M	456.93M	505.28M	400.13M
Cash Flow
Free Cash Flow	57.28M	156.76M	18.31M	25.92M	4.11M	4.90M
Operating Cash Flow	64.13M	162.41M	22.71M	33.23M	12.61M	12.98M
Investing Cash Flow	2.59M	-128.88M	42.30M	1.69M	24.86M	75.45M
Financing Cash Flow	-69.06M	-40.22M	-211.27M	-46.13M	-27.25M	-11.88M

COSMO Pharmaceuticals N.V. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 115.80
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CH:COPN, the sentiment is Positive. The current price of 115.8 is above the 20-day moving average (MA) of 111.57, above the 50-day MA of 94.90, and above the 200-day MA of 68.17, indicating a bullish trend. The MACD of 5.56 indicates Positive momentum. The RSI at 65.07 is Neutral, neither overbought nor oversold. The STOCH value of 61.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CH:COPN.

COSMO Pharmaceuticals N.V. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ROG	77 Outperform	CHF279.83B	22.03	31.98%	2.94%	4.77%	-11.07%
BSLN	73 Outperform	CHF657.78M	9.03	―	―	58.51%	―
COPN	69 Neutral	CHF1.95B	35.57	11.46%	1.82%	-3.44%	-21.64%
MED	62 Neutral	CHF1.23B	-2,293.37	―	―	7.29%	-112.70%
KURN	61 Neutral	CHF1.00B	-158.15	-7.82%	―	104.01%	33.25%
MEDX	56 Neutral	CHF472.87M	-80.53	―	4.54%	-2.42%	-222.68%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

COSMO Pharmaceuticals N.V. Corporate Events

Cosmo Pharmaceuticals Sets 9 March 2026 Webcast for 2025 Full-Year Results

Cosmo Pharmaceuticals N.V. will publish its 2025 full-year financial results on 9 March 2026 at 07:00 a.m. CET and will host a live conference call and audio webcast at 10:00 a.m. CET the same day for investors, analysts and journalists. Chief Executive Officer Giovanni Di Napoli and Chief Financial Officer Svetlana Sigalova will present the company’s recent financial and operational performance, outline strategic initiatives, growth opportunities and outlook, and take questions during a Q&A session, with the webcast and presentation to remain accessible online for three months. The company will simultaneously release its 2025 annual report and ESG report on its website, and has flagged key upcoming investor-relations dates on its financial calendar, underscoring its ongoing engagement with the capital markets and broader stakeholder community.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF136.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Enters Scale-Up Phase on Strong 2025 Results and AI, Dermatology Pipeline Momentum

Cosmo Pharmaceuticals reported preliminary 2025 revenues of EUR 104 million, with recurring income driven by GI Genius™ and Winlevi® rising 15% year-on-year to EUR 88 million, and ended the year with more than EUR 128 million in cash and no debt, giving it substantial financial flexibility as it enters a scale-up phase under its Vision 2030 strategy. The company highlighted an operational inflection point with EBITDA at the top end of guidance, the evolution of GI Genius™ into a scalable AI platform including an Apple Vision Pro feasibility study, European regulatory approval for its ColonPRO module, broad international approvals for acne drug Winlevi® ahead of a European launch in 2026, and steady progress in its pipeline for androgenetic alopecia, bile acid diarrhea, distal ulcerative colitis and solid tumors, positioning Cosmo for 2026 value catalysts and potential partnerships that could further strengthen its position in AI-enabled MedTech and dermatology markets.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Unveils Breakthrough Results for Male Hair Loss Treatment

Cosmo Pharmaceuticals announced groundbreaking Phase III results for Clascoterone 5% solution, a potential first major therapeutic breakthrough for male hair loss in over 30 years. The studies showed significant hair count improvements, with one study achieving a 539% increase compared to placebo. The solution, which blocks DHT at the hair follicle receptor, demonstrated a favorable safety profile and could redefine androgenetic alopecia treatment. Cosmo is preparing for regulatory submissions in the USA and Europe, aiming to address a market with significant unmet demand.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF130.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Expands Global Reach with Winlevi® Approval in Brazil

Cosmo Pharmaceuticals N.V. has announced the approval of its acne treatment, Winlevi®, by the Brazilian Health Authority, marking its entry into one of Latin America’s largest dermatology markets. This approval expands Winlevi®’s availability to over 50% of the Latin American population and strengthens Cosmo’s global dermatology presence. The product, which offers a novel approach to acne treatment without systemic hormonal effects, is set to be launched in Brazil by Sun Pharmaceutical Industries Limited. This milestone supports Cosmo’s Vision 2030 growth strategy and enhances its partnership with Sun Pharma.

The most recent analyst rating on (CH:COPN) stock is a Hold with a CHF67.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Advances in Sustainability with Enhanced ESG Rating and EcoVadis Recognition

Cosmo Pharmaceuticals N.V. has achieved significant milestones in its sustainability efforts, receiving an improved ESG rating from S&P Global and an EcoVadis bronze medal for its Italian production site. The company’s S&P Global Corporate Sustainability Assessment rating increased to the 67th percentile, highlighting its success in integrating sustainability into governance, environmental, and social impact areas. Additionally, Cosmo’s partnership with EcoVadis aims to enhance supply chain transparency and risk management, reflecting its commitment to responsible sourcing and continuous improvement in sustainability practices.

The most recent analyst rating on (CH:COPN) stock is a Hold with a CHF67.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals to Engage Investors at Key Conferences

Cosmo Pharmaceuticals N.V. announced its participation in upcoming healthcare investor conferences in London and Windsor, where key executives will engage with investors through presentations and one-on-one meetings. These events are part of Cosmo’s strategy to strengthen investor relations and showcase its leadership in AI-driven healthcare and specialty pharmaceuticals.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.

Cosmo Pharmaceuticals Secures CE Certification for ColonPRO EU, Expanding AI Colonoscopy Platform to Europe

Cosmo Pharmaceuticals N.V. has received CE certification for its ColonPRO EU, an advanced AI software platform for colonoscopy, marking a significant milestone in its expansion into the European market. This certification, following FDA approval in the U.S., underscores Cosmo’s leadership in AI-assisted endoscopy and its commitment to innovation in colorectal cancer prevention, enhancing the company’s market position and offering improved care standards for patients.

The most recent analyst rating on (CH:COPN) stock is a Buy with a CHF77.00 price target. To see the full list of analyst forecasts on COSMO Pharmaceuticals N.V. stock, see the CH:COPN Stock Forecast page.